CPRX vs. SMMT, ARVN, LGND, BMEA, GPCR, CTIC, CRNX, OPK, PLRX, and IDYA
Should you be buying Catalyst Pharmaceuticals stock or one of its competitors? The main competitors of Catalyst Pharmaceuticals include Summit Therapeutics (SMMT), Arvinas (ARVN), Ligand Pharmaceuticals (LGND), Biomea Fusion (BMEA), Structure Therapeutics (GPCR), CTI BioPharma (CTIC), Crinetics Pharmaceuticals (CRNX), OPKO Health (OPK), Pliant Therapeutics (PLRX), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical preparations" industry.
Catalyst Pharmaceuticals vs.
Summit Therapeutics (NASDAQ:SMMT) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.
1.6% of Summit Therapeutics shares are owned by institutional investors. Comparatively, 86.7% of Catalyst Pharmaceuticals shares are owned by institutional investors. 83.7% of Summit Therapeutics shares are owned by company insiders. Comparatively, 14.1% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Catalyst Pharmaceuticals received 185 more outperform votes than Summit Therapeutics when rated by MarketBeat users. Likewise, 74.88% of users gave Catalyst Pharmaceuticals an outperform vote while only 57.06% of users gave Summit Therapeutics an outperform vote.
Summit Therapeutics has a beta of -1.03, suggesting that its stock price is 203% less volatile than the S&P 500. Comparatively, Catalyst Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the S&P 500.
In the previous week, Catalyst Pharmaceuticals had 6 more articles in the media than Summit Therapeutics. MarketBeat recorded 9 mentions for Catalyst Pharmaceuticals and 3 mentions for Summit Therapeutics. Catalyst Pharmaceuticals' average media sentiment score of 0.53 beat Summit Therapeutics' score of 0.45 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.
Catalyst Pharmaceuticals has a consensus target price of $21.50, suggesting a potential upside of 79.47%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Catalyst Pharmaceuticals is more favorable than Summit Therapeutics.
Catalyst Pharmaceuticals has a net margin of 38.76% compared to Summit Therapeutics' net margin of -1,012.41%. Catalyst Pharmaceuticals' return on equity of 34.72% beat Summit Therapeutics' return on equity.
Catalyst Pharmaceuticals has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Catalyst Pharmaceuticals beats Summit Therapeutics on 16 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding CPRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Catalyst Pharmaceuticals Competitors List
Related Companies and Tools